Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...